Generation of Transplantable Beta Cells for Patient-Specific Cell Therapy

Abstract EN

Islet cell transplantation offers a potential cure for type 1 diabetes, but it is challenged by insufficient donor tissue and side effects of current immunosuppressive drugs.

Therefore, alternative sources of insulin-producing cells and isletfriendly immunosuppression are required to increase the efficiency and safety of this procedure.

Beta cells can be transdifferentiated from precursors or another heterologous (non-beta-cell) source.

Recent advances in beta cell regeneration from somatic cells such as fibroblasts could circumvent the usage of immunosuppressive drugs.

Therefore, generation of patient-specific beta cells provides the potential of an evolutionary treatment for patients with diabetes.